| Company | 介绍 | Intro |
| DiaMedica Therapeutics | DiaMedica Therapeutics Inc.是一家处于临床阶段的生物制药公司。公司专注于开发神经系统和肾脏疾病疗法，如急性缺血性中风（AIS）和慢性肾脏疾病（CKD）。公司的主导产品DM199与天然存在的人类卡利克里酶-1（KLK1）蛋白有相似的功能，可保护和恢复中风受损组织的血液循环，并改善整体肾功能。KLK1是一种丝氨酸蛋白酶或蛋白质，主要产生于肾脏、胰腺和唾液腺。DM199疗法有望改善循环和关键系统的整体功能，及减少炎症和氧化。该公司还有其他针对IgA肾病和非裔美国人慢性肾病的产品管线。 | DiaMedica Therapeutics Inc. is a clinical stage biopharmaceutical company committed to improving the lives of people suffering serious diseases. Its lead candidate, DM199, is the first pharmaceutically active recombinant (synthetic) form of the KLK1 protein, an established therapeutic modality for the treatment of acute ischemic stroke and chronic kidney disease. Kailikang (urinary KLK1) currently generates approximately $100M US per year in China and DM199 is a potential next generation recombinant form that addresses challenges with urine derived protein. |
| Astrocyte | Astrocyte Pharmaceuticals是一家药物开发公司，开发用于治疗神经退行性脑损伤的新型神经保护疗法。Astrocyte正在开发专有的小分子药物制剂AST-004，用于中风、创伤性脑损伤或脑震荡患者的急性治疗。该产品将由紧急救援人员或医疗专业人员在受伤后24小时内注射，用于限制神经元损伤和细胞死亡。已完成第一例患者给药。 | Astrocyte Pharmaceuticals is a drug discovery and development company advancing novel neuroprotective therapeutics for the treatment of neurodegenerative brain injuries. Astrocyte is developing the proprietary small molecule pharmaceutical agent AST-004 for acute administration to patients who have suffered a stroke, TBI, or concussion. This product would be by emergency responders or a medical professional within 24 hours of injury to limit neuronal damage and cell death. |
| Yangtze River Pharma | 扬子江药业集团是科技部命名的全国首批创新型企业。其产品管线包括化药、中药、生物药、高端药物制剂和仿制药200多个，研发方向以抗感染、心脑血管、消化系统为主。YZJ-1139作为治疗失眠症的主要候选药物，临床2期初步药效体现，正在进行临床3期实验。 | Yangtze River Pharma is one of the first innovative enterprises in China named by the Ministry of Science and Technology. Our pipeline includes more than 200 chemical drugs, Chinese medicines, biologics, high-end pharmaceutical preparations and generics, with R&D focus on anti-infective, cardiovascular, cerebrovascular and digestive systems. YZJ-1139 is a lead candidate for the treatment of insomnia, with preliminary efficacy in clinical phase 2 and clinical phase 3 trials underway. |
| Rancho Santa Fe Bio | Rancho Santa Fe是一家处于临床阶段的研究心血管治疗的制药公司。主要的研发方向为减缓主动脉瓣狭窄患者的钙化。其主导药物Ataciguat 正在美国、欧盟、英国和加拿大进入治疗进行性主动脉瓣狭窄的临床III期试验。 | Rancho Santa Fe Bio is a clinical stage, calcific disorders platform company based in San Diego. Its lead drug, ataciguat, is entering Phase III clinical trials for the treatment of progressive aortic valve stenosis in the US, the EU, the UK and Canada. |
| Delova Biotech | 清普生物科技是一家以临床需求为导向，聚焦中美双报改良型新药研发的新兴企业。基于自主知识产权的XisGel®技术平台，开发了丰富的产品管线。目前系列改良型非阿片类镇痛药已进入到临床前开发阶段。其核心资产QP001是一种用于术后疼痛管理的美洛昔康注射液，已向FDA提交了pre-NDA申请。 | Delova Biotech is a specialty branded pharmaceutical company, focusing on the development of proprietary formulations of injectable drug products to fulfill unmet medical needs in China and the US. Delova Biotech has a diverse product pipeline built on the advanced patent-protected XisGel® drug delivery platform. So far, the Non-opioid analgesics has entered the preclinical stage. QP001 is a meloxicam injection for postoperative pain management which has been submitted pre-NDA in FDA. |
| Brise Pharmaceuticals | 熙源安健是一家生物技术初创公司，专注于发现、开发和商业化新型生物制药和疼痛管理解决方案。熙源安健旨在将最新的科学发现和多年的药物开发经验转化为开发经济、可靠和创新的疼痛管理解决方案。 其核心资产，BR01T，是一种治疗慢性疼痛的抗体，正在进行临床前测试。 | Brise Pharmaceuticals is an early-stage biotech startup focused on the discovery, development, and commercialization of novel biopharmaceuticals and solutions in pain management. Brise aims to turn the latest scientific discoveries and years of drug development experience into development of affordable, reliable and innovative pain management solutions. Its leading assest, BR01T, is a antibody for Chronic Pain, undergoing pre-clinical testing. |
| NOVASSAY SA | Novassay 是一家活跃在离子通道治疗领域的生物技术公司，研究重点是神经病痛和肿瘤学。其核心资产NVA1309，正被开发用于治疗神经性疼痛，处于临床前研究阶段。可用于广泛的衰弱性疼痛病症，如糖尿病疼痛性神经痛（DPNP）、手术后疼痛（PSP）、带状疱疹后神经痛（PHN）、腰椎病（坐骨神经痛，LR）和纤维肌痛。 | Novassay is a biotech active in the area of Ion Channel therapeutics with focus in neuropathic pain and Oncology. our leading product, NVA1309, is being developed for neuropathic pain, currently at pre-clinical stage. NVA1309 is a drug candidate for a broad range set of debilitating pain conditions such as diabetic painful neuropathic pain (DPNP), post-surgical pain (PSP), post-herpetic neuralgia (PHN), lumbar radiculopathy (sciatica, LR) and fibromyalgia. |
| Altus Formulation | Altus Formulation是一家专业的合同开发和生产组织（CDMO），利用其一系列的差异化技术和其在NCE、NME和增值药物开发方面的丰富经验，为Altus的合作伙伴提供专利保护。Altus Drug Development 提供一系列服务，帮助客户快速、经济高效地将药物从实验室转化到临床再到市场。TrazoFles是一款治疗重度抑郁症的小分子药剂，目前正处于临床三期实验 | Altus Drug Development is a specialist CDMO using their range of differentiating technologies and their vast experience of NCE, NME and Value-Added Medicine development to provide patent-protected new products for their partners. Altus Drug Development offers a range of services to move your drug from Lab to Clinic to Market swiftly and cost-effectively. TrazoFles, a small molecule for the treatment of major depressive disorder, is currently in clinical phase III trials. |
| Anavex Life Sciences | Anavex Life Sciences 公司是一家临床阶段的生物制药公司，从事开发治疗中枢神经系统（CNS）疾病的候选药物，市值为$6.0380亿。Anavex 的主要候选药物 ANAVEX®2-73，已成功完成阿尔茨海默病的 2a 期临床试验、帕金森的 2 期概念验证研究以及 2 期和 3 期研究成年 Rett 综合征患者临床试验。 | Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases. Its lead drug candidate is ANAVEX 2-73, which is in Phase III clinical trial for the treatment of Alzheimer’s disease; Phase III clinical trial to treat pediatric patients with Rett syndrome; Phase II clinical trial for the treatment of Parkinson’s disease. |
BioToChina.org 